Working Parties
What is the EBMT?Related Meetings EBMT logo
MembershipRegistryWorking PartiesNurses GroupDirectoryTransplant GuidelinesCorporate Sponsorship
Chronic Leukaemia
Prospective Clinical Trials
Retrospective Studies
Non-Interventional Studies
Members
Publications
Questionnaire
Study Administration
INTERGROUP CLL AUTOGRAFT TRIAL
MRC + SFGM + GCLLSG + EBMT

The value of autografting in younger patients with high risk CLL

This is a prospective randomised phase III trial designed to determine the outcome of autologous SCT compared to no further treatment at present in patients with high risk CLL who have reached a complete remission (CR), a very good partial remission (VGPR) or a nodular partial remission (NPR) (see appendix I for definitions) after first or second line therapy.


This trial is closed to inclusion.

Trial management center:

EBMT Clinical Trials Office Leiden (The Netherlands)
E-mail: ebmtcto@lumc.nl
Telnr: +31 71 526 9722
(German) Faxnumber: +49 180 500 290 623
(fax to E-mail system)

Study Co-ordinator: Michallet, M

Writing Committee: Dreger P (Kiel), Milligan DW (Birmingham), Kimby E (Huddinge), Meloni G (Rome), Michallet M (Lyon), Van't Veer Mars (Rotterdam), Montserrat E (Barcelona)

Statisticians: Brand R (Leiden), Richards S (Oxford)

Data Manager: Van Os M (Leiden)

Click on the links below to download relevant documents in format

 

 


What is the EBMT? | Related Meetings | Membership | Registry | Working Parties
Nurses Group | Directory | Transplant Guidelines | Corporate Sponsorship

HOME | SITE MAP | RELATED LINKS | CONTACT US